Now we are waiting for the FDA to approve the drug.

[FavStocks]

So you know the biotech market is hot right now especially after VNDA’s 900% gain overnight. People are now trying to find the next hidden gem biotech stock that will multiply your investment.

In the biotech world, FDA decisions can be a gamble but statistics are on your side. 70%-90% of all drugs in Phase 3 testing receive FDA approval. The reason why so many drugs are approved at that point is because most the unsuccessful ones are weeded out in the Phase 1, 2, and 3 trials.

To help you find the next big biotech stock waiting for FDA approval, we are for a limited time giving away a FREE FDA Calendar to the next 1,000 new forum members of the FavStock.com stock forums.

Don’t worry the forum is completely free and the FREE FDA Calendar is actually free, that mean no credit card, no fine print, no games, no BS. This is on a first come first serve biases. Stop by FavStocks.com and get your FREE FDA Calendar now!

http://www.favstocks.com/forum/fda-calendar/

http://www.favstocks.com/forum/



If you’re interested in the following stocks your probably interested in the calendar;
Nephros, Inc. (OTC:NEPH)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
Amgen, Inc. (NASDAQ:AMGN)
Gilead Sciences, Inc. (NASDAQ:GILD)
Celgene Corporation (NASDAQ:CELG)
Geron Corporation (NASDAQ:GERN)

####

About FavStocks.Com

FavStocks.Com is a news portal and forum covering the news and financial sector. It may feature its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars.

For more investment news, go to FavStocks.com. Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. FavStocks.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

[stktr8dr]

I have been following the biomed selection of stocks for approximately 3 months. It has been my experience that the FDA is not currently meeting their PDUFA approval decisions according to their projected calendar dates.

Most credible sources attribute the lag to insufficient staffing levels at that FDA. What percentage of "on time" decisions do you believe the FDA has been making in 2009?

[Canada]

I have been following the biomed selection of stocks for approximately 3 months. It has been my experience that the FDA is not currently meeting their PDUFA approval decisions according to their projected calendar dates.

Most credible sources attribute the lag to insufficient staffing levels at that FDA. What percentage of "on time" decisions do you believe the FDA has been making in 2009?

I could not give you what percentage of "on time" decisions FDA delivered, but 90% of the time they failed to make decision on time in this year (may be I am little week in math )

[stktr8dr]

Federal funding for the FDA is scheduled to rise to 2.35 billion in FY2010, 298.6 million above FY2009. The money will contain 3 critical components for FDA:
1. 134million for the foods center and field activities
2. 44 million for the drugs center and field activities
3. 35 million for the medical devices center and field activities

With these increases, FDA will hire additional inspectors and conduct more domestic and foreign food and medical products inspections.

The increased staff for inspections and other internal processes within the FDA will hopefully assure the approvals will be completed in a more timely manner. Great news (IMO) for us as investors.

[reachkantish]

I invested in INSV after FDA approval. But, it is going only downhill since. No one seems to be interested in it.

[kingAndI]

I have been following the biomed selection of stocks for approximately 3 months. It has been my experience that the FDA is not currently meeting their PDUFA approval decisions according to their projected calendar dates.

Most credible sources attribute the lag to insufficient staffing levels at that FDA. What percentage of "on time" decisions do you believe the FDA has been making in 2009?

[kingAndI]

I invested in INSV after FDA approval. But, it is going only downhill since. No one seems to be interested in it.

I invested in anpi a month ago and now it droped like a rock.

[aravind]

You should have invested immediately after the FDA approval for INSV.

[mtlmoody]

Most of the times, lagging FDA approval also have adverse effect on s.p. I think NRI might get it on time as thisis their third attempt with few requirements only..

[fdastock]

Federal funding for the FDA is scheduled to rise to 2.35 billion in FY2010, 298.6 million above FY2009. The money will contain 3 critical components for FDA:
1. 134million for the foods center and field activities
2. 44 million for the drugs center and field activities
3. 35 million for the medical devices center and field activities

With these increases, FDA will hire additional inspectors and conduct more domestic and foreign food and medical products inspections.

The increased staff for inspections and other internal processes within the FDA will hopefully assure the approvals will be completed in a more timely manner. Great news (IMO) for us as investors.

are you sure?